UY38148A - Composiciones inmunogénicas de ehv que contienen ul18 y/o ul8 inactivados - Google Patents
Composiciones inmunogénicas de ehv que contienen ul18 y/o ul8 inactivadosInfo
- Publication number
- UY38148A UY38148A UY38148A UY38148A UY38148A UY 38148 A UY38148 A UY 38148A UY 38148 A UY38148 A UY 38148A UY 38148 A UY38148 A UY 38148A UY 38148 A UY38148 A UY 38148A
- Authority
- UY
- Uruguay
- Prior art keywords
- ehv
- inactivated
- immunogenic compositions
- present
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16041—Use of virus, viral particle or viral elements as a vector
- C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16051—Methods of production or purification of viral material
- C12N2710/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16061—Methods of inactivation or attenuation
- C12N2710/16062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
- C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16762—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere al campo de las vacunas (de vectores), y en especial, a EHV novedosos que tienen una inactivación de UL18 y/o UL8. La presente invención también se refiere a casetes de expresión y vectores relacionados, que son adecuados para expresar genes de interés, en especial, secuencias que codifican un antígeno. Los vectores virales de la presente invención son útiles para producir una composición inmunógena o vacuna.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18162630 | 2018-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38148A true UY38148A (es) | 2019-10-01 |
Family
ID=61691807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY38148A UY38148A (es) | 2018-03-19 | 2019-03-19 | Composiciones inmunogénicas de ehv que contienen ul18 y/o ul8 inactivados |
Country Status (16)
Country | Link |
---|---|
US (1) | US11384365B2 (es) |
EP (1) | EP3768307A1 (es) |
JP (2) | JP7273840B2 (es) |
KR (1) | KR20200132958A (es) |
CN (1) | CN111867625A (es) |
AR (1) | AR115002A1 (es) |
AU (1) | AU2019239562A1 (es) |
BR (1) | BR112020019268A2 (es) |
CA (1) | CA3091954A1 (es) |
CL (1) | CL2020002195A1 (es) |
EA (1) | EA202092164A1 (es) |
MX (1) | MX2020009724A (es) |
PH (1) | PH12020551442A1 (es) |
TW (1) | TW202003026A (es) |
UY (1) | UY38148A (es) |
WO (1) | WO2019179998A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019237413A1 (en) * | 2018-03-19 | 2020-09-24 | Boehringer Ingelheim Vetmedica (China) Co., Ltd. | Recombinant virus capable of stably expressing target proteins |
AU2020404933A1 (en) * | 2019-12-16 | 2022-06-30 | Oregon Health & Science University | Multi-specific T cell receptors |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US382425A (en) | 1888-05-08 | Brandt | ||
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
IE872748L (en) | 1986-10-16 | 1988-04-16 | Arjomari Europ | Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
WO1990001543A1 (fr) | 1988-07-29 | 1990-02-22 | Intracel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
ATE240401T1 (de) | 1989-03-21 | 2003-05-15 | Vical Inc | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
EP0620277A1 (en) | 1993-03-18 | 1994-10-19 | Merck & Co. Inc. | Nucleic acid pharmaceuticals |
FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
CA2181832C (en) | 1994-01-27 | 2012-11-27 | Harriet L. Robinson | Immunization by inoculation of dna transcription unit |
ES2243937T3 (es) | 1994-04-29 | 2005-12-01 | Baxter Healthcare S.A. | Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños. |
WO1996029421A1 (en) | 1995-03-23 | 1996-09-26 | Cantab Pharmaceuticals Research Limited | Vectors for gene delivery |
JP2002512501A (ja) | 1996-07-03 | 2002-04-23 | メリアル インコーポレイテッド | 外来性dnaを含む組換えイヌアデノウィルス(cav) |
GB9626029D0 (en) | 1996-12-14 | 1997-01-29 | Univ Leeds | EVH-1 vectors |
US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
JP2002508976A (ja) * | 1998-01-14 | 2002-03-26 | ヒューマン ジーン セラピー リサーチ インスティテュート | 遺伝子療法において使用するための、免疫原性が低下したヌクレオチド発現システム |
AR040601A1 (es) * | 2002-07-19 | 2005-04-13 | Boehringer Ingelheim Vetmed | Mutantes ehv negativos de gm sin elementos heterologos |
EP1394258A1 (en) | 2002-08-30 | 2004-03-03 | Geneart GmbH | Non-human herpesviruses as vectors |
WO2009051823A2 (en) * | 2007-10-18 | 2009-04-23 | Michigan State University | Bacterial artificial chromosome containing feline herpes virus type 1 genome and uses thereof |
MX2011000535A (es) | 2008-07-23 | 2011-02-22 | Boehringer Ingelheim Pharma | Nuevos elementos reguladores. |
MX2011003535A (es) * | 2008-10-03 | 2011-09-21 | Novartis Ag | Composiciones de virus de herpes bovino-1, vacunas, y metodos. |
US20130195918A1 (en) * | 2011-08-08 | 2013-08-01 | Dennis J. O'Callaghan | Equine Herpesvirus 1 Vaccine and Vector and Uses Thereof |
CN105535959A (zh) | 2015-12-30 | 2016-05-04 | 暨南大学 | 单纯性疱疹病毒i型ul18基因缺失减活疫苗的制备方法 |
CN105641692A (zh) | 2015-12-30 | 2016-06-08 | 暨南大学 | 单纯疱疹病毒ⅰ型基因重组减毒活疫苗及其制备方法 |
-
2019
- 2019-03-19 CN CN201980019028.0A patent/CN111867625A/zh active Pending
- 2019-03-19 US US16/358,519 patent/US11384365B2/en active Active
- 2019-03-19 BR BR112020019268-6A patent/BR112020019268A2/pt unknown
- 2019-03-19 MX MX2020009724A patent/MX2020009724A/es unknown
- 2019-03-19 EA EA202092164A patent/EA202092164A1/ru unknown
- 2019-03-19 JP JP2020550179A patent/JP7273840B2/ja active Active
- 2019-03-19 WO PCT/EP2019/056804 patent/WO2019179998A1/en unknown
- 2019-03-19 KR KR1020207029731A patent/KR20200132958A/ko unknown
- 2019-03-19 AR ARP190100692A patent/AR115002A1/es unknown
- 2019-03-19 TW TW108109321A patent/TW202003026A/zh unknown
- 2019-03-19 CA CA3091954A patent/CA3091954A1/en active Pending
- 2019-03-19 EP EP19711366.5A patent/EP3768307A1/en active Pending
- 2019-03-19 UY UY38148A patent/UY38148A/es unknown
- 2019-03-19 AU AU2019239562A patent/AU2019239562A1/en active Pending
-
2020
- 2020-08-26 CL CL2020002195A patent/CL2020002195A1/es unknown
- 2020-09-11 PH PH12020551442A patent/PH12020551442A1/en unknown
-
2022
- 2022-10-13 JP JP2022164602A patent/JP2023012474A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202003026A (zh) | 2020-01-16 |
US11384365B2 (en) | 2022-07-12 |
US20190284577A1 (en) | 2019-09-19 |
CA3091954A1 (en) | 2019-09-26 |
EP3768307A1 (en) | 2021-01-27 |
AU2019239562A1 (en) | 2020-08-13 |
JP2021516061A (ja) | 2021-07-01 |
WO2019179998A1 (en) | 2019-09-26 |
BR112020019268A2 (pt) | 2021-01-05 |
MX2020009724A (es) | 2020-10-08 |
JP2023012474A (ja) | 2023-01-25 |
KR20200132958A (ko) | 2020-11-25 |
JP7273840B2 (ja) | 2023-05-15 |
AR115002A1 (es) | 2020-11-18 |
PH12020551442A1 (en) | 2021-08-23 |
EA202092164A1 (ru) | 2021-02-10 |
CL2020002195A1 (es) | 2021-01-22 |
CN111867625A (zh) | 2020-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37406A (es) | Nuevo sitio de inserción orf70 de ehv | |
CY1121528T1 (el) | Ανασυνδυασμενοι φορεις ερπητοϊου gallid 3 (mdv οροτυπου 2) που εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων | |
CY1124254T1 (el) | Μεθοδοι και συνθεσεις για την προκληση προστατευτικης ανοσιας εναντι λοιμωξης ιου της ανθρωπινης ανοσοανεπαρκειας | |
CY1119436T1 (el) | Σκευασμα για αντισωμα εναντι- 4 7 | |
CL2019000704A1 (es) | Vectores de adenovirus canino. | |
CL2019000705A1 (es) | Nuevos promotores. | |
CL2020002195A1 (es) | Ehv novedoso con ul18 y/o ul8 inactivados | |
CO2019011548A2 (es) | Vacunas contra el gallid herpesvirus 3 recombinante que codifican antígenos patogénicos aviares heterólogos | |
CO2019014677A2 (es) | Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos | |
BR112018006567A2 (pt) | vacinas de partículas semelhantes a vírus (vlp) do parvovirus canino (cpv) e seus usos | |
EA201990010A1 (ru) | Вакцина против вируса инфекционного бронхита | |
CL2017003224A1 (es) | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante | |
ECSP18081582A (es) | Constructos de alfavirus vivo atenuado y métodos y usos de los mismos | |
CO2022004470A2 (es) | Vectores de herpesvirus de los pavos recombinante que expresan antígenos de patógenos aviares y usos de estos | |
CL2020000606A1 (es) | Sistema de expresión de paramyxoviridae. | |
EA202092165A1 (ru) | Новый ehv сайт инсерции ul43 | |
MX2019006244A (es) | Construcciones de vectores virales para la expresion de adyuvantes geneticos que activan la ruta sting. | |
AR105134A1 (es) | Vacunas contra la influenza con coincidencia antigénica | |
MX2022001430A (es) | Formulaciones de vacuna contra chikungu?a. | |
MX2022000525A (es) | Vacunas contra la ehrlichia y composiciones inmunogenicas. | |
UY36328A (es) | Vacunas de fmdv recombinante y usos de las mismas |